Crigler-Najjar syndrome type 1 (CN1) is an inherited disorder characterized by the absence of hepatic uridine diphosphoglucuronate glucuronosyltransferase (UDPGT), the enzyme responsible for the conjugation and excretion of bilirubin. We performed allogenic hepatocyte transplantation (AHT) in a child with CN1, aiming to improve bilirubin glucuronidation in this condition. A 9-year-old boy with CN1 was prepared with plasmapheresis and immunosuppression with prednisolone and tacrolimus. When a graft was made available, 7.5 × 10 9 hepatocytes were isolated and infused into the portal vein percutaneously. After 2 weeks phenobarbitone was added to promote the enzymatic activity of UDPGT of the transplanted hepatocytes. Nocturnal phototherapy was continued throughout the studied period. Total bilirubin was considered a reliable marker of allogenic cell function. There was no significant variation of vital signs nor complications during the infusion. Mean ± SD bilirubin level was 530 ± 38 µmol/L before and 359 ± 46 µmol/L after AHT (t-test, p < 0.001). However, the introduction of phenobarbitone was followed by a drop of tacrolimus level with increase of alanine aminotransferase (ALT) and increase of bilirubin. After standard treatment of cellular rejection bilirubin fell again but from then on it was maintained at a greater level. After discharge the patient experienced a further increase of bilirubin that returned to predischarge levels after readmission to the hospital. This was interpreted as poor compliance with phototherapy. Only partial correction of clinical jaundice and the poor tolerability to nocturnal phototherapy led the parents to refuse further hepatocyte infusions and request an orthotopic liver transplant. After 24 months the child is well, with good liver function on tacrolimus and prednisolone-based immunosuppression. Isolated AHT, though effective and safe, is not sufficient to correct CN1. Maintenance of adequate immunosuppression and family compliance are the main factors hampering the success of this procedure.
INTRODUCTION
shown to be sufficient to avoid OLT. Following the demonstration that AHT is feasible, the challenge of the Crigler-Najjar syndrome type 1 (CN1) is an autosocurrent study was to perform several hepatocyte infumal recessive disorder characterized by a severe, chronic, sions and better understand the reasons for failure to nonhemolytic, unconjugated hyperbilirubinemia resultmaintain in vivo viability of these cells in the long term. ing from the absence of hepatic uridine diphosphoglu-Our aim was therefore to restore UDPGT activity in a curonate glucuronosyltransferase (UDPGT), the enzyme child with CN1 by AHT, focusing on events affecting responsible for the conjugation and excretion of bilirucell function following the infusion. bin (4,5,7,16). The standard treatment of CN1 so far has been orthotopic liver transplantation (OLT) (10) . The re-MATERIALS AND METHODS placement of the whole organ by OLT is curative but carries surgical risks and precludes the benefits of new A 9-year-old boy with severe unconjugated hyperbilirubinaemia and a clinical diagnosis of CN1 was referred techniques hopefully available in the future, such as gene therapy. Allogenic hepatocyte transplantation (AHT) to our center to be considered for OLT. The child already had clinical signs of kernicterus, including devel-has been performed in inborn errors of metabolism (8, 9, 13, 20) . Despite that the technique has been shown opmental delay, slurred speech, and mild ataxia. Magnetic resonance imaging was compatible with kernicterus. to be safe and effective, isolated infusions have not been 152 AMBROSINO ET AL.
The confirmation of the diagnosis of CN1 was based on of immune reactions or cross-infections (2, 11, 19) . The resulting suspension contained single cells along with the following findings: total bilirubin under 16 h a day of phototherapy of around 500 µmol/L, with a conju-small clusters of hepatocytes (1). The viability of the hepatocytes was determined by the trypan blue dye ex-gated fraction lower than 20 µmol/L; lack of response to phenobarbitone; absent signs of hemolytic disorders. clusion test before each infusion time and was 80% and 60%, respectively. Samples from the cell suspension After discussion with the parents who provided written informed consent and once approval was obtained were collected for microbiological tests, including bacteria, endotoxin, fungi, and mycoplasma. Aliquots of liver from the ethical committee of the University of Padua, the child was considered for AHT. cells were stored for DNA analysis and future reference.
Infusion of Hepatocytes Patient Preparation
After listing for liver transplantation, a percutaneous The child was admitted to the Paediatric Intensive Care Unit and continuous monitoring of portal pressure, transhepatic portal catheter was inserted under sedation, followed by a portogram and a CT scan with contrast to central venous pressure, arterial blood pressure, transcutaneous saturation of O 2 , and ECG was commenced. Light check the correct positioning and flow pattern in the portal system. The CT scan showed that the left lobe was sedation with midazolam 0.1 mg/kg/h and antibiotic prophylaxis with cephazolin and teicoplanin were started. preferentially perfused by the stream of contrast although the catheter was correctly placed in the portal trunk. A Systemic heparinization with sodium heparin infusion (starting with 10 U/kg/h), adjusting the dose to achieve continuous infusion of 3 ml/h of NaCl 0.9% with sodium heparin 1 U/ml was maintained in the portal cathe-an activated partial thromboplastin time (APTT) of about 40 s or an activated clotting time (ACT) of 220-240 ter. The child was then started on plasmapheresis every 3-4 days through a subclavian venous line, intensive was initiated, followed by administration of methylprednisolone 10 mg/kg intravenously in 10 min, and then phototherapy, and calcium carbonate 20 mg/kg four times a day. Immunosuppression with tacrolimus (levels 20 mg/kg during the infusion of the hepatocytes. The hepatocytes were administered in two consecutive ali-around 10 µmol/L) was commenced.
quots of 300 ml of Ringer lactate solution shaken and Isolation of Hepatocytes oxygenated continuously (Jatem-macchi; Mod. 1C-1000 oxygenator) containing 3.5×10 9 and 4.0 × 10 9 cells, re-Once an ABO matched graft was made available it was retrieved and perfused with cold Belzer solution (3). spectively, and infused in 2 h each separated by a 2-h break. Cells for the second infusion were maintained on The donor was a 47-year-old man who died from a cerebral vascular accident. A split liver technique was per-ice during the first infusion process. After 6 h from the end of the infusion the portal cath-formed. The left lobe was dissected, with the left artery and left portal vein. The right lobe was transplanted into eter was removed under fluoroscopy, provided the visualization of the portal venous system at portogram. In an adult patient with end-stage liver disease, leaving the left lobe for hepatocyte isolation that was started about order to avoid bleeding during the catheter extraction, an intraparenchymal embolization was performed (Spong-5 h following cross-clamping. The left liver lobe was maintained on ice and transported to the laboratory for ostan, Johnson & Johnson-Medical Limited Gargrave, Skipton, UK). cell isolation. Once in the laboratory, the graft was perfused with collagenase type IV at a concentration of 0.05
Follow-Up g/ml in phosphate buffer solution (PBS, Seromed) supplemented with 5 mmol of calcium chloride at a temper-Daily Doppler ultrasound for 3 days to rule out portal vein thrombosis was performed. A week after the infu-ature of 37°C at a flow rate of 200 ml/min through the left branch of the portal vein and left hepatic artery. The sion oral phenobarbitone was added to enhance the enzymatic activity of the transplanted hepatocytes. Medi-two perfused segments were shred and passed through a digestion chamber. Then the liver cells (90% hepato-cal treatment and follow-up were otherwise the same as for patients receiving an OLT, as described previously cytes and approximately 10% nonparenchymal cells by morphological evaluation) were filtered through three (6). Daily serum bilirubin levels were measured to provide an estimate of the engraftment and function of the silk mesh filters of different porosity from 500 down to 200 µm. Liver cells were suspended in cold Dulbecco's transplanted hepatocytes. Total bilirubin was considered a reliable marker of in vivo cell viability. Nocturnal pho-modified Eagle's medium (DMEM/Ham's F-12, Seromed) supplemented with 10% fetal calf serum (Sigma) totherapy was continued throughout the study period. A liver biopsy was taken on day 30 and the liver fragment and washed three times following 100 × g × 5 min centrifugations. Fetal calf serum has been used safely for and saliva DNA were extracted with a forensic DNA kit (Biotek Omega, USA). PCR was carried out using an cell suspensions in human studies despite the concerns AmpFISTR Profiler plus kit and short tandem repeat pliance to nocturnal phototherapy the child was readmitted to the hospital and bilirubin dropped again to (STR) fragments were separated using the ABI Prism 310 Genetic Analyzer (Applied Biosystems, USA) (15) . a mean level of 352 µmol/L (range 321-389). We adapted the AmpFlSTR Profiler Plus kit commer-Further Parameters During the Follow-Up cialized as human identification system, which we used Tacrolimus. Tacrolimus levels were maintained at for chimerism analysis after allogenic bone marrow around 10 µmol/L in the first 10 days post-AHT (phase transplantation (BMT). For the interpretation of mixed 1) and then dropped down to 6-8 µmol/L between day pattern donor-and recipient-specific peaks a standard-15 and day 35 after AHT (phase 2). After day 35 tacroliized approach was validated. Due to the high number of mus levels were maintained between 10 and 12 µmol/L. markers, the method is very helpful when a sex mis-This drop of tacrolimus followed the administration of match analysis is not possible.
phenobarbitone and was considered to be due to enzy-RESULTS matic induction. Tacrolimus levels returned to desired values after progressive and substantial increase of the Safety and Tolerability of the Infusion administered dose (Fig. 2 ). Hepatocyte infusion was carried out in 6 h with no ALT. From day 35 post-AHT (phase 3) alanine amisignificant variation of vital signs apart from an increase notransferase (ALT, normal values <55 IU/L) went up in portal pressure from 5 to a maximum and transient to 355 IU/L at day 40, and then came back to normal peak of 12 mmHg. Central venous pressure remained after 1 month, approximately at day 85 post-AHT (phase below 3 mmHg and heart rate, arterial blood pressure, 4). Such increase of ALT followed the drop of tacroliand transcutaneous saturation of O 2 were constantly mus levels and the spike of bilirubin (Fig. 2) . No eviwithin the normal ranges throughout the procedure. There dence of infections or other complications during the were no thrombotic complications. The child was always 146-day follow-up after AHT were detected. awake during the infusion and was discharged from the Only partial correction of clinical jaundice and the intensive care unit the following day. The child was decreased tolerability to nocturnal phototherapy by the never intubated and the only drugs used for catheter pochild led the parents to complain of a very poor quality sitioning and removal were midazolam and ketamine.
of life and to request an OLT, performed successfully on day 146 post-AHT. Comparing the DNA of the donor Engraftment and Efficacy liver before AHT, and saliva of the recipient, the hepatoof the Transplanted Hepatocytes cytes of a needle liver biopsy taken at day 40 post-AHT Total bilirubin dropped significantly following AHT and the native liver explanted 146 days after AHT chifrom a mean ± SD level of 530 ± 38 µmol/L before merism could not be demonstrated. AHT (in the period of maximized phototherapy during After 12 months from OLT the child is well, with hospitalization) to values as low as 267 µmol/L. Howgood liver function on tacrolimus-and prednisoloneever, to further detail the effect of AHT and the complibased immunosuppression. cations observed during the follow-up, we deliberately identified five phases post-AHT ( Fig. 1) .
Statistical Analysis Phase 1 (days 0-14): Bilirubin dropped to a mean level
The Student t-test between pre-and post-AHT biliof 362 µmol/L, showing a more pronounced decrease rubin levels showed a significant drop of bilirubin (p < at around days 12-14 post-AHT. 0.0001). The same test applied to phase 3 versus phase Phase 2 (days 15-35): In this period bilirubin mean 5 levels showed a significant increase of mean bilirubin level was 395 µmol/L; at day 29 total bilirubin spiked levels (p < 0.0001). to levels as high as 600 µmol/L (equivalent to pre-DISCUSSION AHT values). This was interpreted as rejection and treated with pulsed steroids as previously described Crigler-Najjar syndrome type 1 is a unique condition in which the liver architecture is completely normal and (6). Following steroids administration bilirubin started decreasing.
the enzymatic defect causes the accumulation of a single metabolite, unconjugated bilirubin. The jaundiced child Phase 3 (days 36-60): Bilirubin remained stable at a mean level of 317 µmol/L (range 267-369). with CN1 is managed easily with phototherapy as long as the body surface area, physiologically greater in in-Phase 4 (days 61-90): Bilirubin increased again to mean levels of 381 µmol/L (range 301-443). In this period fants, allows adequate exposure of skin to light with inactivation of toxic bilirubin. Typically, approaching ado-the child had been discharged and was followed as an outpatient. lescence, phototherapy becomes less effective and the child is committed to lie under the lamps not only over-Phase 5 (days 91-146): Because of suspected poor com- night while sleeping but also during the day. This leads hepatocytes engraft, and also considering the flow-dependent distribution following the infusion in the portal to poor quality of life and also leads to underperformance of these subjects in physical and mental skills.
vein, we were not surprised by the difficulty of locating donor cells within the native liver. Nevertheless, physi-However, the most worrying complication of such condition is the sudden rise of unconjugated bilirubin, often cians dealing with CN patients know that such consistent and prolonged decrease in bilirubin cannot be attrib-triggered by infections, with development of irreversible kernicterus (5). For these reasons liver transplantation uted simply to fluctuations seen in this condition. It is possible that very few surviving cells can produce a no-has been advocated, which has been the treatment of choice for CN1 (21). OLT carries surgical and medical ticeable biochemical difference of bilirubin conjugation in patients with CN1. Despite the initial success of the risks and condemns the patients to carry a graft for their whole life. Another option considered in CN1 has been procedure, we faced several problems that led us to perform an OLT in this child. One of the difficulties we performing auxiliary partial orthotopic liver transplant, a technique that, preserving a lobe of the native liver, encountered was maintaining a level of tacrolimus steadily greater than 10 µmol/L. This was probably due to offers the chance for gene therapy once available. This technique requires better surgical expertise and more the enzymatic induction caused by phenobarbitone that was added to promote UDPGT activity in the trans-careful follow-up than OLT and is not comparable to AHT as far as invasiveness and costs are concerned planted hepatocytes. In fact, this was followed by a drop of the calcineurin inhibitor level despite progressive in- (17, 22) . All these reasons justify the attempt to decrease bilirubin levels by AHT.
crease of the dose. This undesirable event allowed us to evaluate the effect of decreased immunosuppression in With this study we have confirmed that AHT is a good alternative to OLT in CN1. Whereas OLT carries such a setting. The increase of bilirubin during phase 2 of the follow-up and of ALT shortly afterwards were, risks, is expensive and definitive, AHT in our experience is safe, effective, and inexpensive. Moreover, hepa-in this perspective, interpreted as cellular rejection that apparently responded to pulsed intravenous steroids and tocyte transplantation could be performed with a minimally invasive technique, without the need for general optimization of tacrolimus levels (Figs. 1 and 2) . Interestingly, after the drop in tacrolimus levels, we observed anesthesia or assistance for airway control.
Despite a significant and sustained reduction in se-first a remarkable increase of bilirubin and afterwards the increase of ALT (Figs. 1 and 2) . Although this is not rum bilirubin, the analysis of a biopsy taken during the study and the evaluation of the explanted liver after OLT what is seen during rejection of a liver graft, also the previous reports on AHT referred to episodes of rejec-did not demonstrate donor DNA in the liver tissue. A variety of methods have been used to evaluate cell engraft-tion lacking the typical biochemical features commonly expected after OLT (8, 9, 13, 20) . It cannot be excluded ment following transplantation, including immunoglobulin allotyping, sex chromosome analysis, cytogenetic that rejection could present differently in AHT when compared to OLT. It has been shown in animal models analysis, red blood cell phenotyping, and restriction fragment length polymorphisms (RFLP), each of which have that proinflammatory cytokines such as those observed during cellular rejection affect UDPGT activity, decreas-limitations. The application of PCR-based technology has greatly enhanced the ability to detect small amounts ing glucuronidation with a dose-dependent mechanism (12) . If the amount of cells synthesizing UDPGT in the of host or donor cells. We used a technique based on determination of chimeric status by short tandem repeat liver is 100%, such as after OLT, there is probably enough enzyme to overcome the inhibition of proinflam-(STR) markers that was described as useful for monitoring minimal residual disease in patients after allogenic matory cytokines during cellular rejection. Conversely, if there is only 2% of cells synthesizing UDPGT a par-stem cell transplantation for hematological disorders. This technique has been described as able to detect as tial inhibition of its activity could be sufficient to worsen the jaundice in such patient. We speculated that the in-few as 1% of the chimeric cell population in the BMT setting (14, 15) . However, it is not validated for detection flammatory response caused by cellular rejection initially inhibited UDPGT activity and later led to cell ly-of chimerism in solid organ transplants and it is possible that the method might not have been sensitive enough sis, with loss of part of the transplanted hepatocytes. The relatively higher levels of bilirubin we were able to in this setting. Moreover, in other experiments of hepatocyte transplantation the presence of a sex mismatch achieve thereafter (phase 5 vs. phase 3) support the hypothesis that some cells were lost after the increase of between donor and recipient could have favored the detection of chimerism in the recipient organ (8) .
ALT, in keeping with cellular rejection. It is interesting to notice that in the published AHT literature, an episode Assuming that 7.5 billion cells is approximately 5% of the hepatic cell mass and considering that, as pre-of rejection is frequently suspected but concomitant elevation of transaminases has not been reported (8, 9, 13 , viously suggested, probably less than half of the infused 20). The same mechanism mediated by proinflammatory the cells' efficacy in the long term and on the need to perform several hepatocyte infusions to succeed. molecules may be responsible for the delayed drop of bilirubin following the procedure (phase 1, Fig. 1 
), pos-
We have found that a common problem is the occurrence of what is likely an episode of rejection. This oc-sibly due to the cytokine storm caused by the infusion.
Although the reduction in bilirubin levels was pre-curs often because of insufficient immunosuppression. Probably, in presence of inflammatory cytokines, the cisely what would have been expected based on the mass of cells transplanted and the previously published transplanted cells are inhibited and halt their function. If the insult is not removed the cells are destroyed and results (8) , the family became impatient with the persistent, though mild, jaundice and opted for an OLT, obvi-the efficacy of the procedure cannot be entirely rescued. Another problem we faced was the disappointment of ating an opportunity to correct the metabolic defect by further cell infusions. A report by Seppen et al. (18) sug-the parents after partial correction of the defect, despite thorough explanation before the procedure, and the aver-gests that as little as 10% of a normal amount of hepatic UDPGT activity might be sufficient to normalize biliru-sion to go on with further infusions of cells. Additional studies will be required to determine if bin levels. An estimate of approximately 10% UDPGT activity being able to provide a near total correction of bilirubin levels can be normalized by cell therapy alone. The possibility to perform multiple hepatocyte infusions, bilirubin levels is supported by the hepatocyte transplant studies. In the present case a transplantation of 5% of a better preparation of the family, a more careful maintenance of adequate immunosuppression, and overall the the liver mass resulted in a 50-65% correction in the bilirubin levels. These data suggest that if a second effort to better understand the factors affecting the in vivo viability of transplanted allogenic hepatocytes are transplant was as effective as the first, one could estimate that it would require two or perhaps three separate warranted to make this procedure more effective in the long term. cell infusions to provide normalization of bilirubin levels and relief of clinical symptoms of the disease, such
